Docking Studies of Derivates Phenylaminopyrimidines (PAP) As SARS-Cov-2 Main Protease Inhibitors †
Total Page:16
File Type:pdf, Size:1020Kb
Proceedings Docking Studies of Derivates Phenylaminopyrimidines (PAP) as SARS-Cov-2 Main Protease Inhibitors † Abel Suárez-Castro *, Valeria Muñoz-Gutiérrez, Ma. Guadalupe Villa-Lopez, Claudia Contreras- Celedón, Luis Chacón-García and Carlos J. Cortes-García * Laboratorio de Diseño Molecular, Instituto de Investigaciones Químico Biológicas, Universidad Michoacana de San Nicolás de Hidalgo, Ciudad Universitaria, C.P. 58033 Morelia, Mexico † Presented at the 24th International Electronic Conference on Synthetic Organic Chemistry, 15 November– 15 December 2020; Available online: https://ecsoc-24.sciforum.net/. Received: date; Accepted: date; Published: date Abstract: A set of 18 imine-phenylaminopyrimidines (imine-PAP) 5a–r against the main protease of SARS-CoV-2, is presented. In addition, these compounds have been previously reported by our group. The best receptor-ligand interactions were obtained from 10i, 10m and 10o as shown by their predicted free Gibbs −9.83, −9.71 and −9.02 kcal/mol respectively. This is in comparison with the co- crystalized ligand in the main protease (−7.78 kcal/mol,). These results provide solid foundation in order to test the imine-PAP compounds in in vitro studies in order to explore the possible inhibition of the main protease of SARS-CoV-2. Keywords: phenylaminopyrimidines; molecular docking; main protease; SARS-CoV-2 1. Introduction Coronavirus disease 2019 or COVID-19 is currently a pandemic disease caused by a new coronavirus strain known as SARS-CoV-2 that have infected and killed millions of people worldwide [1,2]. To date, there is no specific antiviral drug for the treatment of COVID-19 and the fastest solution has been drug repurposing. Only the remdesivir has been recently approved (authorized) by the FDA in the treatment for COVID-19, but only for treating certain patients [3–6]. Therefore, there are many efforts to find and develop a new specific antiviral drug. In this way, computer aided drug design (CADD) has played a special role in these efforts, being a powerful in silico tool to predict the possible interactions of small molecules in the active site of the principal target of SARS-CoV-2 namely Mpro protease [7–9]. Thus, molecular docking studies have been suitable for this objective as they confer, a reliable method to predict thousands and millions of small compounds that might inhibit this target SARS-Cov-2 [10]. On the other hand, phenylaminopyrimidines (PAP) are considered privileged nucleus because they have been utilized as a main component of many pharmaceutical drugs, such as imatinib 1, ceritinib 2, etravirine 3 and rilpivirine 4 (Figure 1) [11]. Notably, that last two drugs are used for the treatment of HIV-1 infections. Having in mind the above facts, we present molecular docking studies of a set of 18 imine-phenylaminopyrimidines (imine-PAP) 5a–r previously synthetized in our laboratory [12] against the main protease of SARS-CoV-2. Proceedings 2020, 4, x; doi: FOR PEER REVIEW www.mdpi.com/journal/proceedings Proceedings 2020, 4, x FOR PEER REVIEW 2 of 7 Figure 1. Studied molecules for molecular docking and drugs with PAP scaffold. 2. Materials and Methods 2.1. Computational Details 2.1.1. Ligand Preparation The structures of compounds 5a–r (Figure 2) were modeled as 2D structures with the software ChemBio Drawltra 12.0 [13] and were converted into 3D structures in MDL format. Their protonated states were then computed using the online tool Chemicalize (www.chemicalize.org) [14]. The geometries of the compounds and co-crystalized ligand were calculated at the semiempirical AM1 level in the Gaussian 16 software package [15]. Finally, using Autodock Tools [16], the ligands were prepared by adding polar hydrogens and Gasteiger charges and rotatable (i.e., single) bonds were assigned by default, and a pdbqt file was generated. Figure 2. Phenylaminopyrimidines 5a–r evaluated as SARS-Cov-2 main protease inhibitors. Proceedings 2020, 4, x FOR PEER REVIEW 3 of 7 2.1.2. Receptor Preparation The X-ray coordinates of the Mpro protease receptor of SARS-CoV-2 were retrieved from the Protein Data Bank (PDB code:6LU7) [17]. Molecular water was removed from the crystallographic structure and the final preparation and minimization of the receptor structure was carried out using the Dock Prep module of Chimera software [18] using the AMBER-ff14SB force field. Lastly, Kollman charges were added using Autodock Tools and a pdbqt file was generated. 2.1.3. Docking Calculations Rigid receptor molecular docking was carried out in Autodock4 using the Lamarckian genetic algorithm [19]. We used grid maps with 70 × 70 × 70 points in the active site of the receptor with the coordinates x = −12.202, y = 11.499, z = 69.669, and a grid-point spacing of 0.375 Å. AD4.dat parameters were applied to all of the ligands. The parameters used were 10 runs, a population size of 100, and a run-termination criterion of a maximum of 27,000 generations or a maximum of 10,000,000 energy evaluations. The visualization and analysis of the nonbonded interactions as hydrogen bonds of the best poses were carried out using Discovery Studio Visualizer software [20]. 3. Results and Discussion To explore the possible modes of interaction of compounds 5a–r against Mpro protease receptor of SARS-CoV-2, molecular docking studies were carried out according with the specifications redacted. The predicted free energy and affinity constant values are listed in Table 1, including the predicted free energy for the co-crystalized ligand (N3) in the PDB code 6LU7 [21]. Table 1. Free energy (ΔG) and affinity constant (ki and pki) values predicted from the results of molecular dockings of compounds 5a–r with Mpro protease receptor of SARS-CoV-2. Compound ΔG (kcal/mol) ki (nM) pki 5a −8.17 1,030 5.99 5b −8.21 961.56 6.02 5c −8.34 772.92 6.11 5d −8.67 443.92 6.35 5e −8.28 859.13 6.07 5f −7.87 1,710 5.77 5g −8.19 999.33 6.00 5h −8.93 286.58 6.54 5i −9.83 62.73 7.20 5j −8.90 297.89 6.53 5k −7.97 1,440 5.84 5l −7.97 1,440 5.84 5m −9.71 75.81 7.12 5n −8.50 587.57 6.23 5o −9.02 243.2 6.61 5p −8.47 621.18 6.21 5q −8.47 614.61 6.21 5r −8.29 833.27 6.08 N3 −7.78 1,700 2.77 Proceedings 2020, 4, x FOR PEER REVIEW 4 of 7 Compounds 5a–r showed good predicted free energy compared with the N3 ligand. It is important to note that the N3 is a peptide (Figure 3.) and it has been tested against other SARS-CoV and other MERS-CoV viruses [22] with good outcomes of inhibition for Mpro. The key reported amino acids in the active site are His41 and Cys145, which play a role as a catalytic dyad, and where the main efforts are focused to find Mpro inhibitors. Figure 3. Co-crystalized N3 ligand in 6LU7. According to our docking results, five of PAP compounds showed the best predicted free energy: 5h, 5i, 5j, 5m and 5o (Figure 4) and their substituents at the aromatic or heteroaromatic scaffolds have π-electrons that contribute to form the main interactions between ligands and the active site of the receptor Figure 4. Phenylaminopyrimidines with the best predicted free energies and ki values. The principal interactions of the best predicted free energy compounds are depicted in Table 2. The PAP moiety showed a hydrogen bond almost in all the tested compounds with Gly143, His164, and Glu166, being the most important predicted interaction in our in silico results. On the other hand, the same PAP moiety showed, in some cases, a π-anion or π-sigma interaction with Glu166 becoming the second most important predicted interaction. Compounds 5i and 5m showed the best free energy predicted (−9.83 and −9.71 kcal/mol respectively) and possess an aromatic 4-phenyl pyridine and a O-benzyl moiety, respectively. These aromatic scaffolds contain π electrons that could interact with other π-systems or with electron rich atoms such as sulphur in cysteine. Proceedings 2020, 4, x FOR PEER REVIEW 5 of 7 Table 2. Results of docking studies of 5a–r Phenylaminopyrimidines. Compound Residues of Interaction Type of Interaction Gly143 Hydrogen bond 5h His41 π-π Glu166 π-anion Gly143 Hydrogen bond His41 π-π 5i Met49 π-sulfur Glu166 π-sigma His41 π-π Cys145 π-sulfur 5j His164 Hydrogen bond Met165 π-sulfur Glu166 Hydrogen bond 5m Cys145 π-sulfur Met165 π-sulfur Glu166 Hydrogen bond 5o His163 Hydrogen bond Met165 π-sulfur It is important to highlight that 5h, 5i and 5j showed π–π interactions with His41 (Figure 5A– C), a key amino acid in the active site, contributing with approximately 2–3 kcal/mol to the ligand- receptor interaction. Conversely, 5j and 5m showed a π-sulfur interaction with the Cys145 residue. This kind of interactions are not common in the ligand-receptor poses and show that they could contribution to the possible inhibition of Mpro. (A) (B) (C) (D) Proceedings 2020, 4, x FOR PEER REVIEW 6 of 7 (E) Figure 5. Poses of the best predicted PAP ligands into the active site of Mpro protease of SARS-CoV-2. (A): 5h; (B): 5i; (C): 5j, (D): 5m; (E): 5o. 4. Conclusions The importance of the design and development of inhibitors against SARS-CoV-2 have become a priority in the pharmaceutical sphere. Many efforts are in progress and in many cases computer aided drug discovery is a tool to start with the identification of possible inhibitors in any step of SARS-CoV-2 replication cycle.